Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) fell 4% on Wednesday . The company traded as low as $39.36 and last traded at $39.43, with a volume of 239,204 shares changing hands. The stock had previously closed at $41.08.

A number of research firms have recently weighed in on PCRX. Zacks Investment Research raised Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 target price for the company in a research note on Wednesday, August 10th. BMO Capital Markets reissued a “sell” rating and issued a $36.00 target price on shares of Pacira Pharmaceuticals in a research note on Friday, August 5th. Brean Capital reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 5th. Wedbush reissued an “outperform” rating and issued a $105.00 target price (down previously from $109.00) on shares of Pacira Pharmaceuticals in a research note on Thursday, August 4th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $81.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 3rd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Pacira Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $73.64.

The stock’s market cap is $1.48 billion. The firm has a 50-day moving average price of $40.19 and a 200-day moving average price of $47.09.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.16. The business had revenue of $69.60 million for the quarter, compared to analysts’ expectations of $67.80 million. The business’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.20 earnings per share. Analysts expect that Pacira Pharmaceuticals Inc. will post $0.42 earnings per share for the current fiscal year.

In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld sold 900 shares of Pacira Pharmaceuticals stock in a transaction on Monday, June 6th. The shares were sold at an average price of $46.95, for a total value of $42,255.00. Following the transaction, the director now directly owns 2,950 shares of the company’s stock, valued at $138,502.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Kristen Marie Williams sold 600 shares of Pacira Pharmaceuticals stock in a transaction on Monday, June 6th. The stock was sold at an average price of $47.20, for a total transaction of $28,320.00. Following the completion of the transaction, the chief accounting officer now directly owns 6,900 shares in the company, valued at $325,680. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Pacira Pharmaceuticals stock. KBC Group NV boosted its stake in Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) by 2,685.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,024 shares of the company’s stock after buying an additional 27,018 shares during the period. KBC Group NV owned about 0.08% of Pacira Pharmaceuticals worth $2,152,000 at the end of the most recent reporting period.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.